[go: up one dir, main page]

WO2002074279A2 - Formulation for treating body odour - Google Patents

Formulation for treating body odour Download PDF

Info

Publication number
WO2002074279A2
WO2002074279A2 PCT/IB2002/000771 IB0200771W WO02074279A2 WO 2002074279 A2 WO2002074279 A2 WO 2002074279A2 IB 0200771 W IB0200771 W IB 0200771W WO 02074279 A2 WO02074279 A2 WO 02074279A2
Authority
WO
WIPO (PCT)
Prior art keywords
formulation
weight
hexamine
zinc oxide
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2002/000771
Other languages
French (fr)
Other versions
WO2002074279A3 (en
Inventor
Srdjan Mihailovic
George Mavromichalos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AU2002238803A priority Critical patent/AU2002238803A1/en
Publication of WO2002074279A2 publication Critical patent/WO2002074279A2/en
Publication of WO2002074279A3 publication Critical patent/WO2002074279A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/27—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom

Definitions

  • THIS invention relates to a formulation for treating body odour, in particular for treating foot odour.
  • a formulation for treating body odour, in particular foot odour comprising a combination of hexamine and zinc oxide or pharmaceutically acceptable salts thereof, typically formulated in solution, alone or in combination with one or more pharmaceutically acceptable excipients and/or carriers.
  • An aqueous formulation preferably comprises 0,5 to 10% hexamine by weight of the formulation and 0,5 to 2% zinc oxide by weight of the formulation.
  • the formulation preferably comprises calcium carbonate, talcum, glycerine (glycerol) and distilled water.
  • the invention also covers a powder formulation for treating body odour, in particular foot odour, the formulation comprising a combination of hexamine and zinc oxide or pharmaceutically acceptable salts thereof, typically formulated in solution, alone or in combination with one or more pharmaceutically acceptable excipients and/or carriers.
  • the powder can be applied to a person's skin in an affected area by sprinkling, or rubbing.
  • the hexamine powder may be present in an amount of 30% to 50%, preferably 40% by weight of the composition.
  • Zinc oxide, micronised talc and calcium carbonate are each present in an amount of 10% to 30%, preferably 20% by weight of the composition.
  • the invention extends to the use of a combination of hexamine and zinc oxide in a method of making a medicament for treating body odour, in particular foot odour, and also to the use of this combination in the treatment of body odour, particularly foot odour.
  • the topical formulation of the invention for treating body odour, in particular foot odour comprises a combination of hexamine and zinc oxide, or pharmaceutically acceptable salts thereof, alone or in combination with pharmaceutically acceptable excipients or carriers.
  • the formulation is preferably provided as an aqueous solution, which can be applied to a person's skin in the affected area by way of spraying, coating or any other appropriate form.
  • the hexamine and zinc oxide are both added to the aqueous solution in powder form, typically in an amount of 0,5% to 10% hexamine powder by weight of the formulation, and 0,5% to 2% by weight of the formulation zinc oxide powder.
  • the hexamine powder is present in an amount of 2% to 4% by weight and zinc oxide powder in an amount of 1% to 2% by weight.
  • the additional components in the preferred aqueous formulation of the invention include calcium carbonate, preferably in powder form, talcum, preferably pharmaceutical grade talcum powder, glycerine, (glycerol), preferably in liquid form, and the remainder distilled water. These additional components are preferably provided in amounts of 0,5 to 2% by weight calcium carbonate powder, 0,5 to 2% by weight talcum powder, 1 to 10% by weight glycerine liquid, and 90 to 99% by weight distilled water, respectively.
  • the formulation may, however, be provided as a powder which can be applied to a person's skin in an affected area by sprinkling, or rubbing.
  • hexamine powder is present in an amount of 30% to 50%, preferably 40% by weight of the composition.
  • Zinc oxide, micronised talc and calcium carbonate are each present in an amount of 10% to 30%, preferably 20% by weight of the composition.
  • a 100* batch topical treatment aqueous formulation of the invention can be formulated from the following components.
  • 80* of water is placed into a mixing tank. 4kg of hexamine powder, 2kg of zinc oxide, 2kg of talc powder and 2kg calcium carbonate are added to the water in the mixing tank, with continuous mixing at a low speed. The hexamine dissolves into the water and the zinc oxide, talc powder and calcium carbonate form a suspension in the water. The 8J5kg glycerine is then added to the suspension while continuously mixing. Thereafter, the mixer is stopped and an additional 1 ,25* of purified water is added to make up the 100* batch formulation.
  • the batch may then be decanted into suitable containers for application and sale, for example 30ml containers.
  • suitable containers for application and sale, for example 30ml containers.
  • the zinc oxide powder, calcium carbonate and talcum powder may settle to the bottom of the container, these ingredients are very easy to re-suspended by merely shaking the container before use.
  • the container is preferably a plastic spray pump.
  • Tests were carried out on 5 individuals who were afflicted with foot odour problems. A solution as formulated above was applied to the affected areas for three consecutive nights after bathing or just before bedtime. The individuals' shoes were also treated. All of the patients reported relief by the third application which relief persisted for at least six months after treatment.
  • a 10kg batch topical treatment powder formulation of the invention can be formulated from the following components:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

This invention relates to a formulation for treating body odour, in particular foot odour. The formulation comprises a combination of hexamine and zinc oxide or pharmaceutically acceptable salts thereof. The formulation is preferably an aqueous formulation, but it may be a powder formulation.

Description

FORMULATION
BACKGROUND OF THE INVENTION
THIS invention relates to a formulation for treating body odour, in particular for treating foot odour.
SUMMARY OF THE INVENTION
According to the invention there is provided a formulation for treating body odour, in particular foot odour, the formulation comprising a combination of hexamine and zinc oxide or pharmaceutically acceptable salts thereof, typically formulated in solution, alone or in combination with one or more pharmaceutically acceptable excipients and/or carriers. An aqueous formulation preferably comprises 0,5 to 10% hexamine by weight of the formulation and 0,5 to 2% zinc oxide by weight of the formulation.
In order to be suitable for topical application, the formulation preferably comprises calcium carbonate, talcum, glycerine (glycerol) and distilled water.
The invention also covers a powder formulation for treating body odour, in particular foot odour, the formulation comprising a combination of hexamine and zinc oxide or pharmaceutically acceptable salts thereof, typically formulated in solution, alone or in combination with one or more pharmaceutically acceptable excipients and/or carriers. The powder can be applied to a person's skin in an affected area by sprinkling, or rubbing.
In a powder formulation, the hexamine powder may be present in an amount of 30% to 50%, preferably 40% by weight of the composition. Zinc oxide, micronised talc and calcium carbonate are each present in an amount of 10% to 30%, preferably 20% by weight of the composition.
The invention extends to the use of a combination of hexamine and zinc oxide in a method of making a medicament for treating body odour, in particular foot odour, and also to the use of this combination in the treatment of body odour, particularly foot odour.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENT
The topical formulation of the invention for treating body odour, in particular foot odour, comprises a combination of hexamine and zinc oxide, or pharmaceutically acceptable salts thereof, alone or in combination with pharmaceutically acceptable excipients or carriers.
The formulation is preferably provided as an aqueous solution, which can be applied to a person's skin in the affected area by way of spraying, coating or any other appropriate form.
The hexamine and zinc oxide are both added to the aqueous solution in powder form, typically in an amount of 0,5% to 10% hexamine powder by weight of the formulation, and 0,5% to 2% by weight of the formulation zinc oxide powder. In particular, the hexamine powder is present in an amount of 2% to 4% by weight and zinc oxide powder in an amount of 1% to 2% by weight.
The additional components in the preferred aqueous formulation of the invention include calcium carbonate, preferably in powder form, talcum, preferably pharmaceutical grade talcum powder, glycerine, (glycerol), preferably in liquid form, and the remainder distilled water. These additional components are preferably provided in amounts of 0,5 to 2% by weight calcium carbonate powder, 0,5 to 2% by weight talcum powder, 1 to 10% by weight glycerine liquid, and 90 to 99% by weight distilled water, respectively.
The formulation may, however, be provided as a powder which can be applied to a person's skin in an affected area by sprinkling, or rubbing.
In this case hexamine powder is present in an amount of 30% to 50%, preferably 40% by weight of the composition. Zinc oxide, micronised talc and calcium carbonate are each present in an amount of 10% to 30%, preferably 20% by weight of the composition. The topical treatment formulations of the invention will now be described by way of the following non-limiting examples.
EXAMPLE 1
A 100* batch topical treatment aqueous formulation of the invention can be formulated from the following components.
Figure imgf000005_0001
80* of water is placed into a mixing tank. 4kg of hexamine powder, 2kg of zinc oxide, 2kg of talc powder and 2kg calcium carbonate are added to the water in the mixing tank, with continuous mixing at a low speed. The hexamine dissolves into the water and the zinc oxide, talc powder and calcium carbonate form a suspension in the water. The 8J5kg glycerine is then added to the suspension while continuously mixing. Thereafter, the mixer is stopped and an additional 1 ,25* of purified water is added to make up the 100* batch formulation.
The batch may then be decanted into suitable containers for application and sale, for example 30ml containers. Although the zinc oxide powder, calcium carbonate and talcum powder may settle to the bottom of the container, these ingredients are very easy to re-suspended by merely shaking the container before use. The container is preferably a plastic spray pump.
Tests were carried out on 5 individuals who were afflicted with foot odour problems. A solution as formulated above was applied to the affected areas for three consecutive nights after bathing or just before bedtime. The individuals' shoes were also treated. All of the patients reported relief by the third application which relief persisted for at least six months after treatment.
EXAMPLE 2
A 10kg batch topical treatment powder formulation of the invention can be formulated from the following components:
Figure imgf000006_0001

Claims

1. A formulation for treating body odour comprising a combination of hexamine and zinc oxide or pharmaceutically acceptable salts thereof.
2. A formulation according to claim 1 , formulated as an aqueous solution.
3. The formulation according to claim 2, comprising 0,5 to 10% hexamine by weight of the formulation and 0,5 to 2% zinc oxide by weight of the formulation.
4. The formulation according to claim 3, comprising 2% to 4% hexamine by weight of the formulation and 1 % to 2% zinc oxide by weight of the formulation.
5. The formulation according to any one of the preceding claims, further comprising calcium carbonate, talcum, and glycerine (glycerol).
6. The formulation according to claim 5, comprising 0,5 to 2% by weight calcium carbonate powder, 0,5 to 2% by weight talcum powder, 1 to 10% by weight glycerine liquid, and 90 to 99% by weight distilled water.
7. The formulation according to claim 1 , formulated as a powder.
8. The formulation according to claim 7, comprising from 30% to 50% hexamine by weight of the formulation, 10% to 30% zinc oxide by weight of the formulation, 10% to 30% talcum powder by weight of the formulation and 10% to 30% calcium carbonate by weight of the formulation.
9. The formulation according to claim 8, comprising 40% hexamine by weight of the formulation, 20% zinc oxide by weight of the formulation, 20% talcum powder by weight of the formulation and 20% calcium carbonate by weight of the formulation.
10. Use of a combination of hexamine and zinc oxide in a method of making a medicament for use in a method of treating body odour.
11. Use according to claim 10 in a method of treating foot odour.
12. A combination of hexamine and zinc oxide for use in a method of treating body odour.
13. A combination according to claim 12 for use in a method of treating foot odour.
PCT/IB2002/000771 2001-03-15 2002-03-15 Formulation for treating body odour Ceased WO2002074279A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002238803A AU2002238803A1 (en) 2001-03-15 2002-03-15 Formulation for treating body odour

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA200102163 2001-03-15
ZA2001/2163 2001-03-15

Publications (2)

Publication Number Publication Date
WO2002074279A2 true WO2002074279A2 (en) 2002-09-26
WO2002074279A3 WO2002074279A3 (en) 2002-12-12

Family

ID=25589101

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/000771 Ceased WO2002074279A2 (en) 2001-03-15 2002-03-15 Formulation for treating body odour

Country Status (2)

Country Link
AU (1) AU2002238803A1 (en)
WO (1) WO2002074279A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007096757A3 (en) * 2006-02-23 2008-07-10 Squilset Di Lovato Mariagrazia Tampon for medical use
US20230210738A1 (en) * 2021-12-31 2023-07-06 Sislan (Zhuhai) Pharmaceutical Technology Co. Ltd. Low-Skin Irritating Deodorant Composition And A Method For Preparing Thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1525971A (en) * 1975-02-27 1978-09-27 Hlavin L Deodorant composition
FR2443838A1 (en) * 1978-12-11 1980-07-11 Simovic Rastko Skin cream to reduce perspiration of feet - contg. urotropin, glycerine, zinc oxide and talc
ES2142757B1 (en) * 1998-04-23 2001-04-01 Quimversion S L COMPOSITION IN THE FORM OF ADEQUATE EMULSION FOR THE TREATMENT OF HYPERHYDROSIS AND / OR PLANTAR BROMHIDROSIS

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007096757A3 (en) * 2006-02-23 2008-07-10 Squilset Di Lovato Mariagrazia Tampon for medical use
US20230210738A1 (en) * 2021-12-31 2023-07-06 Sislan (Zhuhai) Pharmaceutical Technology Co. Ltd. Low-Skin Irritating Deodorant Composition And A Method For Preparing Thereof

Also Published As

Publication number Publication date
AU2002238803A1 (en) 2002-10-03
WO2002074279A3 (en) 2002-12-12

Similar Documents

Publication Publication Date Title
JP2000319187A (en) Carbon dioxide transcutaneous and transmucosal absorption composition
US5137718A (en) Infection fighting composition for topical application
JPS62242618A (en) Mercury-containing-antiseptic stabilized ophthalmic remedy
WO2008047680A1 (en) External preparation for skin
JP2001131026A (en) Cosmetic for scalp and hair
JPH069391A (en) Hyaluronidase activity inhibitor
WO2002074279A2 (en) Formulation for treating body odour
US5886038A (en) Composition and method for treatment of psoriasis
AU768917B2 (en) Use of tosylchloramide(s) for treating diseases of the skin, mucous membranes, organs and tissues
JPH11500730A (en) Topical treatment of scar tissue and associated tissue response to trauma
KR101874830B1 (en) Antibacterial Cosmetics Composition
JP3537671B2 (en) Lipolysis accelerator and skin cosmetic for slimming
US20080145461A1 (en) Formulation and method of making a topical pain relief composition
JP3524169B2 (en) Skin cosmetics for acne improvement
JP2007262083A (en) Carbon dioxide percutaneous/transmucosal absorption composition
JP2000212090A (en) Skin-modifying agent
JP3675637B2 (en) Composition for external use
JP3827259B2 (en) Keratinization promoter
JP2019509333A (en) Composition for preventing, improving or treating hair loss comprising deoxycholic acid as an active ingredient
JPS61207326A (en) Skin treating composition
US2697060A (en) Emulsion of the essential oil derived from the western sagebrush
US11780883B2 (en) Derived peptide of lactoferrin and method thereof for promoting and/or increasing lipid synthesis
WO1992002206A1 (en) Lyophilized native collagen sheets comprising cosmetic formulations for the treatment of couperose
JP7301536B2 (en) external composition
CN116019765A (en) Propranolol cream with high transdermal absorption and improvement of keratin hyperplasia and preparation method

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP